OncoGenex Pharmaceuticals (ACHV) Earns News Impact Score of 0.15
Headlines about OncoGenex Pharmaceuticals (NASDAQ:ACHV) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.8480399607928 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, ValuEngine upgraded OncoGenex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th.
Shares of OncoGenex Pharmaceuticals (NASDAQ ACHV) opened at $1.21 on Thursday. OncoGenex Pharmaceuticals has a 12 month low of $1.15 and a 12 month high of $10.23.
ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/oncogenex-pharmaceuticals-achv-earns-news-impact-score-of-0-15/1776159.html.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.